Cargando…

Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus

OBJECTIVE: The American Academy of Ophthalmology recommends a maximum hydroxychloroquine (HCQ) dose of ≤5.0 mg/kg/day to reduce the risk of HCQ-induced retinopathy. To determine if this dose adjustment would have an impact on the clinical course of SLE, we compared outcome measures in a cohort of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez-Otero, Ileana, Medina-Cintrón, Nicolle, Arroyo-Ávila, Mariangelí, González-Sepúlveda, Lorena, Vilá, Luis M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245425/ https://www.ncbi.nlm.nih.gov/pubmed/32434863 http://dx.doi.org/10.1136/lupus-2020-000395

Ejemplares similares

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
por: Osmani, Zgjim, et al.
Publicado: (2021)

Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine
por: Almeida-Brasil, Celline C, et al.
Publicado: (2022)

Coping with systemic lupus erythematosus in patients’ words
por: Cornet, Alain, et al.
Publicado: (2022)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus
por: Jallouli, M, et al.
Publicado: (2014)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Association of patient copayment and medication adherence in systemic lupus erythematosus
por: Lomanto Silva, Raisa, et al.
Publicado: (2023)

Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus
por: Carli, L, et al.
Publicado: (2016)

Complement levels and risk of organ involvement in patients with systemic lupus erythematosus
por: Gandino, Ignacio Javier, et al.
Publicado: (2017)

Serum uric acid is associated with damage in patients with systemic lupus erythematosus
por: Elera-Fitzcarrald, Claudia, et al.
Publicado: (2020)

Living with systemic lupus erythematosus in 2020: a European patient survey
por: Cornet, Alain, et al.
Publicado: (2021)

Attribution of cause of end-stage renal disease among patients with systemic lupus erythematosus: the Georgia Lupus Registry
por: Plantinga, Laura C, et al.
Publicado: (2016)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus
por: Zhu, Lisa, et al.
Publicado: (2022)

Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort
por: Al Sawah, Sarah, et al.
Publicado: (2015)

Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s
por: Albrecht, Katinka, et al.
Publicado: (2014)

Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival
por: Kazzaz, Nayef M, et al.
Publicado: (2015)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
por: Schlencker, Aurelien, et al.
Publicado: (2022)

Association of age with health-related quality of life in a cohort of patients with systemic lupus erythematosus: the Georgians Organized Against Lupus study
por: Plantinga, Laura, et al.
Publicado: (2016)

Rheumatologists’ perspective on hydroxychloroquine guidelines
por: Winebrake, James, et al.
Publicado: (2020)

Perceptions of racism in healthcare among patients with systemic lupus erythematosus: a cross-sectional study
por: Vina, Ernest R, et al.
Publicado: (2015)

Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus
por: Utset, Tammy O, et al.
Publicado: (2015)

Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus
por: Kheir, Joseph M, et al.
Publicado: (2018)

Vitamin D deficiency is common and associated with increased C-reactive protein in children and young adults with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus substudy
por: Robinson, Angela Byun, et al.
Publicado: (2014)

Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners
por: Arat, Seher, et al.
Publicado: (2017)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Use of a screening questionnaire for systemic lupus erythematosus among pregnant women in a Mexican population
por: Lucero-Morales, Luis, et al.
Publicado: (2021)

Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study
por: Su, Kaisheng, et al.
Publicado: (2022)

Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?
por: Fazzari, Melissa J, et al.
Publicado: (2022)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Infection-related hospitalisation in young adults with systemic lupus erythematosus: data from the National Inpatient Sample
por: Dhital, Rashmi, et al.
Publicado: (2023)

Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity
por: Tian, Jingru, et al.
Publicado: (2023)

Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia
por: Arroyo-Ávila, Mariangelí, et al.
Publicado: (2015)

A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2023)

Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre
por: Anastasiou, Christine, et al.
Publicado: (2018)

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?
por: Magder, Laurence S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3k8tua20f64ih3vqb2k4pt0nr